| Name | Title | Contact Details |
|---|
biBerk helps small-business owners find the right insurance policies for their needs without extra costs and hassles. As a part of Warren Buffetts Berkshire Hathaway insurance group, our approach is to help you find the coverage thats right for your business right now. As your business grows, we offer the added insurance products that you need so your coverage grows with you. biBerk can help you with all your small business insurance needs, including: - Workers Compensation - Professional Liability (E&O) - General Liability - Property & Liability (BOP) - Commercial Auto - Umbrella Were also backed by an expert customer service team that can answer any question you throw at them. Well help you find the right insurance policy for your small business. Rated A++ by A.M. Best Company and AAA by Standard & Poors Corporation
WE HELP ATHLETES PUSH LIMITS, CHALLENGE THE STATUS QUO AND STRIVE FOR THAT WHICH IS BEYOND THE HORIZON. Using insights from mountain athletes we have brought to market innovative products such as the Stretch Puffy Jacket focused on solving problems and delivering performance. SYNC is a fast growing performance sport brand building technical apparel for the mountain athlete. Through our single-mindedness and commitment to performance we have been able to deliver true innovation to our consumers.
InterWest was founded in 1992 as a result of the merger of three large successful insurance brokerage firms located in Northern California. Our aggressive entrepreneurial and acquisition efforts have extended our footprint into Central California and the San Francisco Bay Area. Our unyielding commitment to reinvesting in our staff, diversified products & services and innovative technology consistently places us among the top performing insurance and consulting brokerages in the country. We offer unparalleled expertise in all lines of property and casualty, workers compensation, employee benefits and personal insurance coverages, as well as a full range of surety products. Although we operate principally in California, we are licensed to write business in all 50 states and staffed to service clients with locations throughout the nation.
Atlas Battery Limited was incorporated as a public limited Company on October 19, 1966 and its shares are listed on Karachi and Lahore Stock Exchanges in Pakistan. The Company is engaged in manufacture and sales of AGS brand, automotive and motorcycle batteries. The Company has joint venture with GS Yuasa International. Atlas Battery Limited pioneered the manufacture of dry charged Hard Rubber batteries in Pakistan. The company has always been at the vanguard of development in the automotive industry in Pakistan making great strides in the fields research and development. The brand has, over the years, earned a solid reputation as a product of latest Japanese technology with consistently high levels of performance and reliability.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.